Microfluidic paclitaxel-loaded lipid nanoparticle formulations for chemotherapy

Area of Science:

• Pharmaceutical Sciences
• Biotechnology
• Materials Science

Background:

• Nanoparticle technology offers enhanced drug delivery, improving efficacy and reducing toxicity, especially in cancer therapy.
• Liposomes are effective carriers for hydrophobic drugs like paclitaxel, offering low toxicity and prolonged circulation.
• Microfluidic technology provides superior control over nanoparticle formulation compared to conventional methods.

Purpose of the Study:

• To produce paclitaxel-loaded liposomes under 200 nm using microfluidics.
• To investigate the impact of different lipid types and microfluidic parameters on liposome characteristics.
• To evaluate encapsulation efficiency, in vitro drug release, and stability of the formulated liposomes.

Main Methods:

• Liposomes were prepared using microfluidic technology.
• Various lipid compositions (DMPC, DPPC, DSPC, DOPC) and microfluidic parameters (flow rate, flow ratio) were tested.
• Physicochemical properties were analyzed using Dynamic Light Scattering (DLS) and Fourier-Transform Infrared Spectroscopy (FTIR), alongside stability studies.

Main Results:

• Microfluidics allowed for controlled production of liposomes with desired particle size and homogeneity.
• Liposomes formulated with DMPC and DPPC showed promising encapsulation efficiency for paclitaxel.
• In vitro studies demonstrated sustained drug release from the paclitaxel-loaded liposomes.

Conclusions:

• Microfluidic-based liposome preparation is a viable method for developing targeted cancer drug delivery systems.
• Liposome formulations using DMPC and DPPC are effective for encapsulating paclitaxel, leading to sustained release.
• The developed nanoparticle drug delivery system shows potential for improving chemotherapy outcomes.